Pharmacokinetic exposure and treatment outcomes of lenvatinib in patients with renal cell carcinoma and differentiated thyroid carcinoma.
Saved in:
| Title: | Pharmacokinetic exposure and treatment outcomes of lenvatinib in patients with renal cell carcinoma and differentiated thyroid carcinoma. |
|---|---|
| Authors: | Meertens M; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Giraud EL; Department of Pharmacy, Radboud University Medical Centre, Nijmegen, The Netherlands., Hassan E; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Zielhuis SWJ; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Snels TT; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Desar IME; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands., Walraven JEW; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands., Wilgenhof S; Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands., van Thienen JV; Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands., de Boer JP; Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Steeghs N; Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands.; Department of Medical Oncology, Utrecht University Medical Centre, Utrecht University, Utrecht, The Netherlands., van Erp NP; Department of Pharmacy, Radboud University Medical Centre, Nijmegen, The Netherlands., Huitema ADR; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands. a.huitema@nki.nl.; Department of Clinical Pharmacy, Utrecht University Medical Centre, Utrecht University, Utrecht, The Netherlands. a.huitema@nki.nl.; Department of Pharmacology, Princess Máxima Centre for Pediatric Oncology, Utrecht, The Netherlands. a.huitema@nki.nl. |
| Source: | Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2025 Jan 17; Vol. 95 (1), pp. 25. Date of Electronic Publication: 2025 Jan 17. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0843 |
|---|---|
| DOI: | 10.1007/s00280-024-04746-5 |
